Elevated baseline levels of tumor-infiltrating lymphocytes (TILs) have been correlated with higher rates of pCR in HER2-positive breast cancer patients undergoing neoadjuvant HER2-targeted therapy. This evidence concerns the gene ERBB2 and neoplasm.